Please login to the form below

Not currently logged in
Email:
Password:

Pharma and BRIC

This page shows the latest Pharma and BRIC news and features for those working in and with pharma, biotech and healthcare.

Building and delivering market access capabilities in emerging markets

Building and delivering market access capabilities in emerging markets

Within these markets the BRIC countries (Brazil, Russia, India and China) are the dominant players. ... Positioning for growth in BRIC countries is an important strategy for pharma companies.

Latest news

  • All eyes on pharma in Brazil All eyes on pharma in Brazil

    Partnering with big pharma minimises operational risks but, in addition to reduced control over sales, marketing and other processes, royalties rather than sales will diminish sales profitability. ... This article was originally published in the

  • Brazil's healthcare conundrum Brazil's healthcare conundrum

    There is no doubting that Brazil is a major emerging market and one that many big pharma organisations will be keeping a close eye on in the future. ... This article was orginially published in the PME supplement Pharma and BRIC.

  • BRIC 'not delivering' on promises of high growth BRIC 'not delivering' on promises of high growth

    This is according to a new report by analysts Frost &Sullivan, which says that pharma firms expanding into emerging markets like Brazil, Russia, India and China ( BRIC) are realising “there are ... For more on the impact of the BRIC nations, read

More from news
Approximately 1 fully matching, plus 3 partially matching documents found.

Latest Intelligence

  • The MISTs of time - new emerging markets The MISTs of time - new emerging markets

    As the BRIC foundations become firmly established, where next – and how soon – for those pharma companies seeking to exploit the developing markets? ... This article was originally published in the PME supplement Pharma and BRIC.

  • Intellectual property threats in the BRIC markets Intellectual property threats in the BRIC markets

    For as long as pharma and biotech companies have contemplated doing business in BRIC, there have been questions about intellectual property (IP) risk. ... This article was originally published in the PME supplement Pharma and BRIC.

  • The rise of chronic disease in BRIC markets The rise of chronic disease in BRIC markets

    At present, pharma is steadily putting the building bricks in place, but as the BRIC economies mature and local healthcare systems become embedded, the growth opportunities in these key disease areas ... This article was originally published in the

  • A tailored approach to the BRIC markets A tailored approach to the BRIC markets

    There are increasing examples of pharma companies collaborating with governmental and quasi-governmental institutions in BRIC countries. ... This article was originally published in the PME supplement Pharma and BRIC.

  • Building BRICs: pharma's key emerging markets are becoming giants Building BRICs: pharma's key emerging markets are becoming giants

    Pfizer, GSK, Sanofi and Amgen are among the high-profile pharma companies to invest in, or partner with, Brazilian generics manufacturers. ... This article was originally published in the PME supplement Pharma and BRIC.

More from intelligence
Approximately 2 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
dna Communications

Healthcare communications with unique thinking, insight and attitude...

Latest intelligence

Alzheimers
Detecting Alzheimer’s ahead of a cure
A focus on promising new research...
Programmatic methodology and why you should be using it
What is it? How does it work? Why is everyone talking about it? By Richard Webb - Associate Director...
Can you survive without the blue dot?
Or has the digital world has replaced our brain...

Infographics